Unum Therapeutics Inc. (NASDAQ: UMRX): Reassessing Prospects


After grabbing 2.4 million shares, the institutional investor is now in possession of 2.4 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.37% having worth around $6.46 million. Moreover, Renaissance Technologies LLC increased its share by 0.93 million to have a control over 1.19 million shares. And Acadian Asset Management LLC raised its holdings to 0.23 million shares by acquiring 0.35 million shares or 0.92% of the stake.

Unum Therapeutics Inc. (UMRX) concluded trading on 08/26/20 at a closing price of $2.78, with 1.37 million shares of worth about $3.8 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -11.18% during that period and on Wednesday the price saw a loss of about -8.85%. Currently the company’s common shares owned by public are about 31.11M shares, out of which, 27.15M shares are available for trading.

Analysts also issued an outlook of 2.00 for the Unum Therapeutics Inc. stock for next 12 months.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 7 times over the past 12 months. They bought 6,796,362 shares in 6 of the transactions. In 1 selling transactions, insiders dumped 31,873 shares.

Vanguard Total Stock Market Index, Bridgeway Ultra Small Company Mar, and BlackRock Strategic Fds. – Americ are the top 3 mutual funds which are holding stakes in Unum Therapeutics Inc. Vanguard Total Stock Market Index is currently holding 0.4 million shares of worth totaling $1.08 million. The company recently came buying 0.0 shares which brought its stake up to 1.06% of the company’s outstanding shares. Bridgeway Ultra Small Company Mar bought 0.12 million shares, after which its hold over company’s outstanding shares expand to 0.43%, leaving 0.16 million shares with the mutual fund that have a worth of about $0.43 million. BlackRock Strategic Fds. – Americ, after selling 0.15 million shares, have now control over 0.41% of the stake in the company. It holds 7102.0 shares of worth $0.41 million.

Unum Therapeutics Inc. (NASDAQ: UMRX) started trading at $3.10, above $0.05 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $2.78, or with a loss of -8.85%. Stock saw a price change of -11.18% in past 5 days and over the past one month there was a price change of 8.59%. Year-to-date (YTD), UMRX shares are showing a performance of 286.00% which increased to 54.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.29 but also hit the highest price of $3.72 during that period. While comparing its average daily trading volume of 2.77 million shares, we see that about 1.37 million changed hands on the day. The stock is currently trading 2.49% above its 20-day simple moving average (SMA20), while that difference is up 28.28% for SMA50 and it goes to 175.89% higher than SMA200.

Ridgeback Capital Management LP acquired 2.4 million shares of Unum Therapeutics Inc. having value of about $6.46 million. Unum Therapeutics Inc. (NASDAQ: UMRX) currently have 31.11M outstanding shares and institutions hold larger chunk of about 26.50% of that. Holding of mutual funds in the company is about 32.51% while other institutional holders and individual stake holders have control over 76.37% and 2.46% of the stake respectively.

The stock has a current market capitalization of $105.33M. It has posted earnings per share of -$0.75 in the same period. It has Quick Ratio of 2.90 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for UMRX, volatility over the week remained 11.78% while standing at 10.21% over the month.

Analysts are in expectations that Unum Therapeutics Inc. (UMRX) stock would likely to be making an EPS of -$0.04 in the current quarter, while forecast for next quarter ESPS is -$0.04 and it is -$0.17 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.04 which is -$0.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.39 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 24.70% while it is estimated to increase by 63.50% in next year.

Analysts at 1 brokerage firms have issued recommendations for the Unum Therapeutics Inc. (UMRX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wedbush on March 04, 2020 offering a Neutral rating for the stock and assigned a target price of to it. Coverage by Morgan Stanley stated Unum Therapeutics Inc. (UMRX) stock as an Equal-weight in their note to investors on March 03, 2020, suggesting a price target of for the stock.


Please enter your comment!
Please enter your name here